Industry

PLANTATION, Fla.–(BUSINESS WIRE)–Akumin Inc. (together with its subsidiaries “Akumin” or the “Company”) announced today that it entered into an agreement (the “Support Agreement”) with certain noteholders representing over 95% of outstanding senior secured notes due in 2027 and 2028 (together, the “Senior Secured Notes”), and Stonepeak, a leading alternative investment firm, that will reduce debt, … [Read more…]

Deseyne® (vifilcon C) Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia with Extended Depth of Focus (EDOF) Delivers Continuous Vision at All Distances—Redefining Presbyopia Correction BOCA RATON, Fla.–(BUSINESS WIRE)–The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Over The Counter Drugs Market – Global Forecast 2025-2032” report has been added to ResearchAndMarkets.com’s offering. The Over The Counter Drugs Market is experiencing fundamental shifts as self-care gains traction across healthcare models. Senior leaders face complex choices as digitalization, regulatory adjustments, and evolving consumer behaviors redefine sector dynamics and competitive priorities. Market … [Read more…]

The INR 648 crore facility will drive investment in state-of-the-art biologics manufacturing facility in Pipan, Gujarat The facility will enhance technical capabilities, improve global competitiveness, and create long-term, high-value employment across scientific, technical, and operational disciplines AHMEDABAD, India–(BUSINESS WIRE)–Kashiv BioSciences Private Limited (“Kashiv”), a biopharmaceutical company, today announced that it has secured financing of INR … [Read more…]

SUGAR LAND, Texas–(BUSINESS WIRE)–#biopharma–Houston-area clinical research organization Hope Biosciences Research Foundation (HBRF) today shares positive top-line results of a Phase II clinical trial to evaluate Hope Biosciences’ allogeneic adipose‑derived mesenchymal stem cell therapy (HB-adMSCs) for patients with early to moderate Parkinson’s Disease (PD), a condition currently considered incurable that affects approximately one million in the … [Read more…]

DALLAS–(BUSINESS WIRE)–Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Pharmaceutical Filtration: Global Markets” report has been added to ResearchAndMarkets.com’s offering. The global market for pharmaceutical filtration is expected to grow from $12 billion in 2025 and is projected to reach $20.3 billion by the end of 2030, at a compound annual growth rate (CAGR) of 11.1% during the forecast period of 2025 … [Read more…]

LAS VEGAS–(BUSINESS WIRE)–The MolinaCares Accord (“MolinaCares”), in collaboration with Molina Healthcare of Nevada (“Molina”), provided grants to two local food banks to help address rising food insecurity across the state. The donations, totaling $187,000, were given to Three Square Food Bank serving Southern Nevada and Food Bank of Northern Nevada. Both organizations have seen a … [Read more…]

– PDUFA target action date of June 30, 2026 – – Priority Review designation is granted to applications for drugs that, if approved, would be a significant improvement in the safety or effectiveness of treating a serious condition – – Veligrotug now has both Priority Review and Breakthrough Therapy Designations, each following requests which included … [Read more…]

CADEMPINO, Switzerland–(BUSINESS WIRE)–#ClinicalTrial—Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase … [Read more…]